{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T02:44:34Z","timestamp":1794710674133,"version":"4.9.1"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science","award":["JP17K15512"],"award-info":[{"award-number":["JP17K15512"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Critically ill patients are susceptible to serious infections due to their compromised conditions and extensive use of medical devices, often requiring empiric broad-spectrum antimicrobial therapy. Failure of antimicrobial therapy in this vulnerable population has a direct impact on the patient\u2019s survival; hence, selecting the optimal dosage is critical. This population, however, exhibits complex and diverse disease-related physiological changes that can markedly alter antimicrobial disposition. Inflammatory cytokines overexpressed in the systemic inflammatory response syndrome increase vascular permeability, leading to higher volume of distribution for hydrophilic antimicrobials. These cytokines also downregulate metabolic enzyme activities, reducing the clearance of their substrates. Hypoalbuminemia can increase the volume of distribution and clearance of highly protein-bound antimicrobials. Acute kidney injury decreases, while augmented renal clearance increases the clearance of antimicrobials primarily excreted by the kidneys. Furthermore, continuous renal replacement therapy and extracorporeal membrane oxygenation used in critical illness substantially affect antimicrobial pharmacokinetics. The complex interplay of multiple factors observed in critically ill patients poses a significant challenge in predicting the pharmacokinetics of antimicrobials. Therapeutic drug monitoring is the most effective tool to address this issue, and is proactively recommended for vancomycin, teicoplanin, aminoglycosides, voriconazole, \u03b2-lactams, and linezolid in critically ill patients. To streamline this process, model-informed precision dosing is expected to promote personalized medicine for this population.<\/jats:p>","DOI":"10.1186\/s40780-025-00425-6","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T05:15:42Z","timestamp":1742188542000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Pharmacokinetic variability and significance of therapeutic drug monitoring for broad-spectrum antimicrobials in critically ill patients"],"prefix":"10.1186","volume":"11","author":[{"given":"Ryota","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"425_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1469-0691.2007.01835.x","volume":"14","author":"S Blot","year":"2008","unstructured":"Blot S. Limiting the attributable mortality of nosocomial infection and multidrug resistance in intensive care units. Clin Microbiol Infect. 2008;14:5\u201313.","journal-title":"Clin Microbiol Infect"},{"key":"425_CR2","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1179\/acb.2006.037","volume":"61","author":"D Vandijck","year":"2006","unstructured":"Vandijck D, Decruyenaere JM, Blot SI. The value of sepsis definitions in daily ICU-practice. Acta Clin Belg. 2006;61:220\u20136.","journal-title":"Acta Clin Belg"},{"key":"425_CR3","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.amjcard.2024.04.007","volume":"221","author":"C Mannina","year":"2024","unstructured":"Mannina C, Kini A, Carbone A, Neibart E, Bossone E, Prandi FR, et al. Management of systemic inflammatory response syndrome after cardiovascular interventions. Diagnostic, prognostic, and therapeutic implications. Am J Cardiol. 2024;221:84\u201393.","journal-title":"Am J Cardiol"},{"key":"425_CR4","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/BF01709751","volume":"22","author":"JL Vincent","year":"1996","unstructured":"Vincent JL, Moreno R, Takala J, Willatts S, De Mendon\u00e7a A, Bruining H, et al. The SOFA (Sepsis-related organ failure Assessment) score to describe organ dysfunction\/failure. On behalf of the working group on Sepsis-Related problems of the European society of intensive care medicine. Intensive Care Med. 1996;22:707\u201310.","journal-title":"Intensive Care Med"},{"key":"425_CR5","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1111\/jgs.12544","volume":"61","author":"G Dimopoulos","year":"2013","unstructured":"Dimopoulos G, Koulenti D, Blot S, Sakr Y, Anzueto A, Spies C, et al. Critically ill elderly adults with infection: analysis of the extended prevalence of infection in intensive care study. J Am Geriatr Soc. 2013;61:2065\u201371.","journal-title":"J Am Geriatr Soc"},{"key":"425_CR6","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1097\/CCM.0b013e31819da98e","volume":"37","author":"S Blot","year":"2009","unstructured":"Blot S, Cankurtaran M, Petrovic M, Vandijck D, Lizy C, Decruyenaere J, et al. Epidemiology and outcome of nosocomial bloodstream infection in elderly critically ill patients: a comparison between middle-aged, old, and very old patients. Crit Care Med. 2009;37:1634\u201341.","journal-title":"Crit Care Med"},{"key":"425_CR7","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1097\/CCM.0b013e3181a03961","volume":"37","author":"E Reynvoet","year":"2009","unstructured":"Reynvoet E, Vandijck DM, Blot SI, Dhondt AW, De Waele JJ, Claus S, et al. Epidemiology of infection in critically ill patients with acute renal failure. Crit Care Med. 2009;37:2203\u20139.","journal-title":"Crit Care Med"},{"key":"425_CR8","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1001\/jama.2009.1754","volume":"302","author":"JL Vincent","year":"2009","unstructured":"Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302:2323\u20139.","journal-title":"JAMA"},{"key":"425_CR9","doi-asserted-by":"publisher","first-page":"4851","DOI":"10.1128\/AAC.00627-10","volume":"54","author":"M Paul","year":"2010","unstructured":"Paul M, Shani V, Muchtar E, Kariv G, Robenshtok E, Leibovici L. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother. 2010;54:4851\u201363.","journal-title":"Antimicrob Agents Chemother"},{"key":"425_CR10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ajem.2023.11.014","volume":"76","author":"R Jouffroy","year":"2024","unstructured":"Jouffroy R, Holub M, Gilbert B, Travers S, Bloch-Laine E, Ecollan P, et al. Influence of antibiotic therapy with hemodynamic optimization on 30-day mortality among septic shock patients cared for in the prehospital setting. Am J Emerg Med. 2024;76:48\u201354.","journal-title":"Am J Emerg Med"},{"key":"425_CR11","doi-asserted-by":"publisher","first-page":"755","DOI":"10.2165\/00003088-200645080-00001","volume":"45","author":"JA Roberts","year":"2006","unstructured":"Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet. 2006;45:755\u201373.","journal-title":"Clin Pharmacokinet"},{"key":"425_CR12","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.ijantimicag.2012.02.010","volume":"39","author":"AA Udy","year":"2012","unstructured":"Udy AA, Roberts JA, De Waele JJ, Paterson DL, Lipman J. What\u2019s behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance. Int J Antimicrob Agents. 2012;39:455\u20137.","journal-title":"Int J Antimicrob Agents"},{"key":"425_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.addr.2014.07.006","volume":"77","author":"SI Blot","year":"2014","unstructured":"Blot SI, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient\u2013concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev. 2014;77:3\u201311.","journal-title":"Adv Drug Deliv Rev"},{"key":"425_CR14","doi-asserted-by":"publisher","first-page":"21891","DOI":"10.1038\/s41598-022-25967-9","volume":"12","author":"AK Smekal","year":"2022","unstructured":"Smekal AK, Furebring M, Eliasson E, Lipcsey M. Low attainment to PK\/PD-targets for \u03b2-lactams in a multi-center study on the first 72\u00a0h of treatment in ICU patients. Sci Rep. 2022;12:21891.","journal-title":"Sci Rep"},{"key":"425_CR15","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/cid\/ciu027","volume":"58","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, et al. DALI: defining antibiotic levels in intensive care unit patients: are current \u03b2-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014;58:1072\u201383.","journal-title":"Clin Infect Dis"},{"key":"425_CR16","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10096-016-2832-4","volume":"36","author":"H Woksepp","year":"2017","unstructured":"Woksepp H, H\u00e4llgren A, Borgstr\u00f6m S, Kullberg F, Wimmerstedt A, Oscarsson A, et al. High target attainment for \u03b2-lactam antibiotics in intensive care unit patients when actual minimum inhibitory concentrations are applied. Eur J Clin Microbiol Infect Dis. 2017;36:553\u201363.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"425_CR17","doi-asserted-by":"publisher","first-page":"R126","DOI":"10.1186\/cc9091","volume":"14","author":"FS Taccone","year":"2010","unstructured":"Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, Wittebole X, et al. Insufficient \u03b2-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care. 2010;14:R126.","journal-title":"Crit Care"},{"key":"425_CR18","first-page":"1610136","volume":"27","author":"A LK","year":"2021","unstructured":"LK A. Inflammation in focus: the beginning and the end. Pathol Oncol Res. 2021;27:1610136.","journal-title":"Pathol Oncol Res"},{"key":"425_CR19","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1186\/s13054-024-05150-4","volume":"28","author":"L Li","year":"2024","unstructured":"Li L, Zinger J, Sassen SDT, Juffermans NP, Koch BCP, Endeman H. The relation between inflammatory biomarkers and drug pharmacokinetics in the critically ill patients: a scoping review. Crit Care. 2024;28:376.","journal-title":"Crit Care"},{"key":"425_CR20","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1136\/ejhpharm-2021-003089","volume":"29","author":"B Shahrami","year":"2022","unstructured":"Shahrami B, Sefidani Forough A, Khezrnia SS, Najmeddin F, Arabzadeh AA, Rouini MR, et al. Relationship between Amikacin pharmacokinetics and biological parameters associated with organ dysfunction: a case series study of critically ill patients with intra-abdominal sepsis. Eur J Hosp Pharm. 2022;29:e72\u20136.","journal-title":"Eur J Hosp Pharm"},{"key":"425_CR21","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.cmi.2022.02.017","volume":"28","author":"C K\u00f6nig","year":"2022","unstructured":"K\u00f6nig C, Grensemann J, Czorlich P, Schlemm E, Kluge S, Wicha SG. A dosing nomograph for cerebrospinal fluid penetration of meropenem applied by continuous infusion in patients with nosocomial ventriculitis. Clin Microbiol Infect. 2022;28:1022..e9-.e16.","journal-title":"Clin Microbiol Infect"},{"key":"425_CR22","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1093\/jac\/dkm074","volume":"59","author":"PH n der Voort","year":"2007","unstructured":"n der Voort PH, Boerma EC, Yska JP. Serum and intraperitoneal levels of amphotericin B and Flucytosine during intravenous treatment of critically ill patients with Candida peritonitis. J Antimicrob Chemother. 2007;59:952\u20136.","journal-title":"J Antimicrob Chemother"},{"key":"425_CR23","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1002\/cpt.2146","volume":"109","author":"C Lenoir","year":"2021","unstructured":"Lenoir C, Daali Y, Rollason V, Curtin F, Gloor Y, Bosilkovska M, et al. Impact of acute inflammation on cytochromes P450 activity assessed by the Geneva cocktail. Clin Pharmacol Ther. 2021;109:1668\u201376.","journal-title":"Clin Pharmacol Ther"},{"key":"425_CR24","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s13318-023-00852-6","volume":"48","author":"F Liu","year":"2023","unstructured":"Liu F, Aulin LBS, Manson ML, Krekels EHJ, van Hasselt JGC. Unraveling the effects of acute inflammation on pharmacokinetics: A Model-Based analysis focusing on renal glomerular filtration rate and cytochrome P450 3A4-Mediated metabolism. Eur J Drug Metab Pharmacokinet. 2023;48:623\u201331.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"425_CR25","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1128\/AAC.04789-14","volume":"59","author":"MA Encalada Ventura","year":"2015","unstructured":"Encalada Ventura MA, van den Span LF, Groothuis GM, Alffenaar JW. Influence of inflammation on voriconazole metabolism. Antimicrob Agents Chemother. 2015;59:2942\u20133.","journal-title":"Antimicrob Agents Chemother"},{"key":"425_CR26","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1093\/jac\/dkw099","volume":"71","author":"ML Luong","year":"2016","unstructured":"Luong ML, Al-Dabbagh M, Groll AH, Racil Z, Nannya Y, Mitsani D, et al. Utility of voriconazole therapeutic drug monitoring: a meta-analysis. J Antimicrob Chemother. 2016;71:1786\u201399.","journal-title":"J Antimicrob Chemother"},{"key":"425_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000509970","volume":"65","author":"R Tanaka","year":"2020","unstructured":"Tanaka R, Fujioka T, Suzuki Y, Iwao M, Itoh H. A prospective study on the usefulness of initial voriconazole dose adjustment based on CYP2C19 gene polymorphism analysis. Chemotherapy. 2020;65:59\u201364.","journal-title":"Chemotherapy"},{"key":"425_CR28","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/jac\/dkw349","volume":"72","author":"A Veringa","year":"2017","unstructured":"Veringa A, Ter Avest M, van den Span LF, Touw DJ, Zijlstra JG, et al. Voriconazole metabolism is influenced by severe inflammation: a prospective study. J Antimicrob Chemother. 2017;72:261\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"425_CR29","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1093\/jac\/dkad293","volume":"78","author":"C Boglione-Kerrien","year":"2023","unstructured":"Boglione-Kerrien C, Zerrouki S, Le Bot A, Camus C, Marchand T, Bellissant E, et al. Can we predict the influence of inflammation on voriconazole exposure? An overview. J Antimicrob Chemother. 2023;78:2630\u20136.","journal-title":"J Antimicrob Chemother"},{"key":"425_CR30","doi-asserted-by":"crossref","unstructured":"Gatti M, Fornaro G, Pasquini Z, Zanoni A, Bartoletti M, Viale P et al. Impact of inflammation on voriconazole exposure in critically ill patients affected by probable COVID-19-Associated pulmonary aspergillosis. Antibiot (Basel). 2023;12.","DOI":"10.3390\/antibiotics12040764"},{"key":"425_CR31","doi-asserted-by":"publisher","first-page":"106750","DOI":"10.1016\/j.ijantimicag.2023.106750","volume":"61","author":"DA n den Born","year":"2023","unstructured":"n den Born DA, M\u00e4rtson AG, Veringa A, van der Punt NC, Alffenaar JC, et al. Voriconazole exposure is influenced by inflammation: A population Pharmacokinetic model. Int J Antimicrob Agents. 2023;61:106750.","journal-title":"Int J Antimicrob Agents"},{"key":"425_CR32","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1248\/bpb.b22-00097","volume":"45","author":"Y Maeda","year":"2022","unstructured":"Maeda Y, Tanaka R, Tatsuta R, Takano K, Hashimoto T, Ogata M, et al. Impact of inflammation on Intra-individual variation in trough voriconazole concentration in patients with hematological malignancies. Biol Pharm Bull. 2022;45:1084\u201390.","journal-title":"Biol Pharm Bull"},{"key":"425_CR33","doi-asserted-by":"crossref","unstructured":"Tesfamariam NS, Aboelezz A, Mahmoud SH. The impact of augmented renal clearance on Vancomycin pharmacokinetics and pharmacodynamics in critically ill patients. J Clin Med. 2024;13.","DOI":"10.3390\/jcm13082317"},{"key":"425_CR34","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s40262-018-0636-7","volume":"57","author":"I Bilbao-Meseguer","year":"2018","unstructured":"Bilbao-Meseguer I, Rodr\u00edguez-Gasc\u00f3n A, Barrasa H. Isla A and Solin\u00eds M. Augmented renal clearance in critically ill patients: A systematic review. Clin Pharmacokinet. 2018;57:1107\u201321.","journal-title":"Clin Pharmacokinet"},{"key":"425_CR35","first-page":"346","volume":"39","author":"AM Cook","year":"2019","unstructured":"Cook AM, Hatton-Kolpek J. Augmented Ren Clear Pharmacotherapy. 2019;39:346\u201354.","journal-title":"Augmented Ren Clear Pharmacotherapy"},{"key":"425_CR36","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ijantimicag.2016.12.022","volume":"49","author":"AA Udy","year":"2017","unstructured":"Udy AA, Dulhunty JM, Roberts JA, Davis JS, Webb SAR, Bellomo R, et al. Association between augmented renal clearance and clinical outcomes in patients receiving \u03b2-lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial. Int J Antimicrob Agents. 2017;49:624\u201330.","journal-title":"Int J Antimicrob Agents"},{"key":"425_CR37","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1177\/0885066618809688","volume":"35","author":"JP Baptista","year":"2020","unstructured":"Baptista JP, Martins PJ, Marques M, Pimentel JM. Prevalence and risk factors for augmented renal clearance in a population of critically ill patients. J Intensive Care Med. 2020;35:1044\u201352.","journal-title":"J Intensive Care Med"},{"key":"425_CR38","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40560-019-0408-y","volume":"7","author":"KA Morbitzer","year":"2019","unstructured":"Morbitzer KA, Rhoney DH, Dehne KA, Jordan JD. Enhanced renal clearance and impact on Vancomycin Pharmacokinetic parameters in patients with hemorrhagic stroke. J Intensive Care. 2019;7:51.","journal-title":"J Intensive Care"},{"key":"425_CR39","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s12883-020-01771-8","volume":"20","author":"A Lannou","year":"2020","unstructured":"Lannou A, Carrie C, Rubin S, Cane G, Cottenceau V, Petit L, et al. Salt wasting syndrome in brain trauma patients: a pathophysiologic approach using sodium balance and urinary biochemical analysis. BMC Neurol. 2020;20:190.","journal-title":"BMC Neurol"},{"key":"425_CR40","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1111\/jcpt.13193","volume":"45","author":"K Saito","year":"2020","unstructured":"Saito K, Kamio S, Ito K, Suzuki N, Abe K, Goto T. A simple scoring method to predict augmented renal clearance in haematologic malignancies. J Clin Pharm Ther. 2020;45:1120\u20136.","journal-title":"J Clin Pharm Ther"},{"key":"425_CR41","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/nrneph.2011.92","volume":"7","author":"AA Udy","year":"2011","unstructured":"Udy AA, Roberts JA, Lipman J. Implications of augmented renal clearance in critically ill patients. Nat Rev Nephrol. 2011;7:539\u201343.","journal-title":"Nat Rev Nephrol"},{"key":"425_CR42","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1378\/chest.11-1671","volume":"142","author":"AA Udy","year":"2012","unstructured":"Udy AA, Varghese JM, Altukroni M, Briscoe S, McWhinney BC, Ungerer JP, et al. Subtherapeutic initial \u03b2-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest. 2012;142:30\u20139.","journal-title":"Chest"},{"key":"425_CR43","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.ijantimicag.2011.12.011","volume":"39","author":"JP Baptista","year":"2012","unstructured":"Baptista JP, Sousa E, Martins PJ, Pimentel JM. Augmented renal clearance in septic patients and implications for Vancomycin optimisation. Int J Antimicrob Agents. 2012;39:420\u20133.","journal-title":"Int J Antimicrob Agents"},{"key":"425_CR44","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1093\/jac\/dky314","volume":"73","author":"G Wong","year":"2018","unstructured":"Wong G, Briscoe S, McWhinney B, Ally M, Ungerer J, Lipman J, et al. Therapeutic drug monitoring of \u03b2-lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures. J Antimicrob Chemother. 2018;73:3087\u201394.","journal-title":"J Antimicrob Chemother"},{"key":"425_CR45","doi-asserted-by":"publisher","first-page":"106569","DOI":"10.1016\/j.ijantimicag.2022.106569","volume":"59","author":"CM Silva","year":"2022","unstructured":"Silva CM, Baptista JP, Santos I, Martins P. Recommended antibiotic dosage regimens in critically ill patients with augmented renal clearance: A systematic review. Int J Antimicrob Agents. 2022;59:106569.","journal-title":"Int J Antimicrob Agents"},{"key":"425_CR46","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/FTD.0000000000000270","volume":"38","author":"K Hirai","year":"2016","unstructured":"Hirai K, Ihara S, Kinae A, Ikegaya K, Suzuki M, Hirano K, et al. Augmented renal clearance in pediatric patients with febrile neutropenia associated with Vancomycin clearance. Ther Drug Monit. 2016;38:393\u20137.","journal-title":"Ther Drug Monit"},{"key":"425_CR47","doi-asserted-by":"publisher","first-page":"e27654","DOI":"10.1002\/pbc.27654","volume":"66","author":"SF Maarbjerg","year":"2019","unstructured":"Maarbjerg SF, Thorsted A, Kristoffersson A, Friberg LE, Nielsen EI, Wang M, et al. Piperacillin pharmacokinetics and target attainment in children with cancer and fever: can we optimize our dosing strategy? Pediatr Blood Cancer. 2019;66:e27654.","journal-title":"Pediatr Blood Cancer"},{"key":"425_CR48","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1093\/jac\/dkz065","volume":"74","author":"PG Cojutti","year":"2019","unstructured":"Cojutti PG, Maximova N, Schillani G, Hope W, Pea F. Population pharmacokinetics of continuous-infusion Ceftazidime in febrile neutropenic children undergoing HSCT: implications for target attainment for empirical treatment against Pseudomonas aeruginosa. J Antimicrob Chemother. 2019;74:1648\u201355.","journal-title":"J Antimicrob Chemother"},{"key":"425_CR49","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1093\/jac\/dkz270","volume":"74","author":"A Thorsted","year":"2019","unstructured":"Thorsted A, Kristoffersson AN, Maarbjerg SF, Schr\u00f8der H, Wang M, Brock B, et al. Population pharmacokinetics of Piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen. J Antimicrob Chemother. 2019;74:2984\u201393.","journal-title":"J Antimicrob Chemother"},{"key":"425_CR50","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/FTD.0000000000000978","volume":"44","author":"E Amano","year":"2022","unstructured":"Amano E, Tanaka R, Ono H, Tatsuta R, Hashimoto T, Hiramatsu K, et al. Association of Vancomycin trough concentration and clearance with febrile neutropenia in pediatric patients. Ther Drug Monit. 2022;44:543\u201351.","journal-title":"Ther Drug Monit"},{"key":"425_CR51","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1093\/jac\/dkab302","volume":"76","author":"Y Shimamoto","year":"2021","unstructured":"Shimamoto Y, Verstegen RHJ, Mizuno T, Schechter T, Allen U, Ito S. Population pharmacokinetics of Vancomycin in paediatric patients with febrile neutropenia and augmented renal clearance: development of new dosing recommendations. J Antimicrob Chemother. 2021;76:2932\u201340.","journal-title":"J Antimicrob Chemother"},{"key":"425_CR52","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2165\/11539220-000000000-00000","volume":"50","author":"M Ulldemolins","year":"2011","unstructured":"Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet. 2011;50:99\u2013110.","journal-title":"Clin Pharmacokinet"},{"key":"425_CR53","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jpba.2018.11.047","volume":"165","author":"R Tanaka","year":"2019","unstructured":"Tanaka R, Suzuki Y, Goto K, Yasuda N, Koga H, Kai S, et al. Development and validation of sensitive and selective quantification of total and free daptomycin in human plasma using ultra-performance liquid chromatography coupled to tandem mass spectrometry. J Pharm Biomed Anal. 2019;165:56\u201364.","journal-title":"J Pharm Biomed Anal"},{"key":"425_CR54","doi-asserted-by":"publisher","first-page":"114929","DOI":"10.1016\/j.jpba.2022.114929","volume":"219","author":"R Tanaka","year":"2022","unstructured":"Tanaka R, Kai M, Shinohara S, Tatsuta R, Itoh H. A validated UHPLC-MS\/MS method for quantification of total and free tedizolid concentrations in human plasma. J Pharm Biomed Anal. 2022;219:114929.","journal-title":"J Pharm Biomed Anal"},{"key":"425_CR55","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1093\/jac\/dkab499","volume":"77","author":"Y Hanai","year":"2022","unstructured":"Hanai Y, Takahashi Y, Niwa T, Mayumi T, Hamada Y, Kimura T, et al. Clinical practice guidelines for therapeutic drug monitoring of Teicoplanin: a consensus review by the Japanese society of chemotherapy and the Japanese society of therapeutic drug monitoring. J Antimicrob Chemother. 2022;77:869\u201379.","journal-title":"J Antimicrob Chemother"},{"key":"425_CR56","doi-asserted-by":"crossref","unstructured":"Blanco VE, Hernandorena CV, Scibona P, Belloso W, Musso CG. Acute kidney injury Pharmacokinetic changes and its impact on drug prescription. Healthc (Basel). 2019;7.","DOI":"10.3390\/healthcare7010010"},{"key":"425_CR57","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/S0140-6736(11)61454-2","volume":"380","author":"R Bellomo","year":"2012","unstructured":"Bellomo R, Kellum JA, Ronco C. Acute kidney injury. Lancet. 2012;380:756\u201366.","journal-title":"Lancet"},{"key":"425_CR58","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12882-018-0946-x","volume":"19","author":"SH Howitt","year":"2018","unstructured":"Howitt SH, Grant SW, Caiado C, Carlson E, Kwon D, Dimarakis I, et al. The KDIGO acute kidney injury guidelines for cardiac surgery patients in critical care: a validation study. BMC Nephrol. 2018;19:149.","journal-title":"BMC Nephrol"},{"key":"425_CR59","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1378\/chest.10-2371","volume":"139","author":"M Ulldemolins","year":"2011","unstructured":"Ulldemolins M, Roberts JA, Lipman J, Rello J. Antibiotic dosing in multiple organ dysfunction syndrome. Chest. 2011;139:1210\u201320.","journal-title":"Chest"},{"key":"425_CR60","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0167-4943(99)00025-4","volume":"29","author":"H Finney","year":"1999","unstructured":"Finney H, Bates CJ, Price CP. Plasma Cystatin C determinations in a healthy elderly population. Arch Gerontol Geriatr. 1999;29:75\u201394.","journal-title":"Arch Gerontol Geriatr"},{"key":"425_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1254\/jphs.CP0070058","volume":"105","author":"A Tanaka","year":"2007","unstructured":"Tanaka A, Suemaru K, Araki H. A new approach for evaluating renal function and its practical application. J Pharmacol Sci. 2007;105:1\u20135.","journal-title":"J Pharmacol Sci"},{"key":"425_CR62","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1161\/CIRCULATIONAHA.109.919639","volume":"121","author":"C Briguori","year":"2010","unstructured":"Briguori C, Visconti G, Rivera NV, Focaccio A, Golia B, Giannone R, et al. Cystatin C and contrast-induced acute kidney injury. Circulation. 2010;121:2117\u201322.","journal-title":"Circulation"},{"key":"425_CR63","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.2215\/CJN.00690110","volume":"5","author":"K Soto","year":"2010","unstructured":"Soto K, Coelho S, Rodrigues B, Martins H, Frade F, Lopes S, et al. Cystatin C as a marker of acute kidney injury in the emergency department. Clin J Am Soc Nephrol. 2010;5:1745\u201354.","journal-title":"Clin J Am Soc Nephrol"},{"key":"425_CR64","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1053\/j.ajkd.2011.02.389","volume":"58","author":"Z Zhang","year":"2011","unstructured":"Zhang Z, Lu B, Sheng X, Jin N. Cystatin C in prediction of acute kidney injury: a systemic review and meta-analysis. Am J Kidney Dis. 2011;58:356\u201365.","journal-title":"Am J Kidney Dis"},{"key":"425_CR65","doi-asserted-by":"publisher","first-page":"997","DOI":"10.2165\/00003088-200746120-00003","volume":"46","author":"F Pea","year":"2007","unstructured":"Pea F, Viale P, Pavan F, Furlanut M. Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. Clin Pharmacokinet. 2007;46:997\u20131038.","journal-title":"Clin Pharmacokinet"},{"key":"425_CR66","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.1128\/AAC.00828-16","volume":"60","author":"C Roger","year":"2016","unstructured":"Roger C, Wallis SC, Muller L, Saissi G, Lipman J, Lefrant JY, et al. Influence of renal replacement modalities on Amikacin population pharmacokinetics in critically ill patients on continuous renal replacement therapy. Antimicrob Agents Chemother. 2016;60:4901\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"425_CR67","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1093\/jac\/dkw043","volume":"71","author":"C Roger","year":"2016","unstructured":"Roger C, Wallis SC, Louart B, Lefrant JY, Lipman J, Muller L, et al. Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on Ciprofloxacin population pharmacokinetics in critically ill patients. J Antimicrob Chemother. 2016;71:1643\u201350.","journal-title":"J Antimicrob Chemother"},{"key":"425_CR68","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1093\/jac\/dkv349","volume":"71","author":"C Roger","year":"2016","unstructured":"Roger C, Muller L, Wallis SC, Louart B, Saissi G, Lipman J, et al. Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration. J Antimicrob Chemother. 2016;71:464\u201370.","journal-title":"J Antimicrob Chemother"},{"key":"425_CR69","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1159\/000321488","volume":"30","author":"G Choi","year":"2010","unstructured":"Choi G, Gomersall CD, Tian Q, Joynt GM, Li AM, Lipman J. Principles of antibacterial dosing in continuous renal replacement therapy. Blood Purif. 2010;30:195\u2013212.","journal-title":"Blood Purif"},{"key":"425_CR70","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1097\/CCM.0000000000000317","volume":"42","author":"JA Jamal","year":"2014","unstructured":"Jamal JA, Udy AA, Lipman J, Roberts JA. The impact of variation in renal replacement therapy settings on Piperacillin, Meropenem, and Vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens*. Crit Care Med. 2014;42:1640\u201350.","journal-title":"Crit Care Med"},{"key":"425_CR71","doi-asserted-by":"publisher","first-page":"22148","DOI":"10.1038\/s41598-020-79076-6","volume":"10","author":"K Nonoshita","year":"2020","unstructured":"Nonoshita K, Suzuki Y, Tanaka R, Kaneko T, Ohchi Y, Sato Y, et al. Population Pharmacokinetic analysis of doripenem for Japanese patients in intensive care unit. Sci Rep. 2020;10:22148.","journal-title":"Sci Rep"},{"key":"425_CR72","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10047-020-01214-8","volume":"24","author":"D Onichimowski","year":"2021","unstructured":"Onichimowski D, Nosek K, Zi\u00f3\u0142kowski H, Jaroszewski J, Pawlos A, Czuczwar M. Adsorption of Vancomycin, Gentamycin, Ciprofloxacin and Tygecycline on the filters in continuous renal replacement therapy circuits: in full blood in vitro study. J Artif Organs. 2021;24:65\u201373.","journal-title":"J Artif Organs"},{"key":"425_CR73","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1177\/0310057X1204000309","volume":"40","author":"Y Shiraishi","year":"2012","unstructured":"Shiraishi Y, Okajima M, Sai Y, Miyamoto K, Inaba H. Elimination of Teicoplanin by adsorption to the filter membrane during haemodiafiltration: screening experiments for linezolid, Teicoplanin and Vancomycin followed by in vitro haemodiafiltration models for Teicoplanin. Anaesth Intensive Care. 2012;40:442\u20139.","journal-title":"Anaesth Intensive Care"},{"key":"425_CR74","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1525-1594.2007.00460.x","volume":"32","author":"Q Tian","year":"2008","unstructured":"Tian Q, Gomersall CD, Leung PP, Choi GY, Joynt GM, Tan PE, et al. The adsorption of Vancomycin by polyacrylonitrile, polyamide, and polysulfone hemofilters. Artif Organs. 2008;32:81\u20134.","journal-title":"Artif Organs"},{"key":"425_CR75","doi-asserted-by":"publisher","first-page":"R194","DOI":"10.1186\/cc11679","volume":"16","author":"K Shekar","year":"2012","unstructured":"Shekar K, Roberts JA, McDonald CI, Fisquet S, Barnett AG, Mullany DV, et al. Sequestration of drugs in the circuit May lead to therapeutic failure during extracorporeal membrane oxygenation. Crit Care. 2012;16:R194.","journal-title":"Crit Care"},{"key":"425_CR76","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13054-015-0891-z","volume":"19","author":"K Shekar","year":"2015","unstructured":"Shekar K, Roberts JA, McDonald CI, Ghassabian S, Anstey C, Wallis SC, et al. Protein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: results from an ex vivo study. Crit Care. 2015;19:164.","journal-title":"Crit Care"},{"key":"425_CR77","doi-asserted-by":"publisher","first-page":"107078","DOI":"10.1016\/j.ijantimicag.2023.107078","volume":"63","author":"A Jendoubi","year":"2024","unstructured":"Jendoubi A, Pressiat C, De Roux Q, Hulin A, Ghaleh B, Tissier R, et al. The impact of extracorporeal membrane oxygenation on antifungal pharmacokinetics: A systematic review. Int J Antimicrob Agents. 2024;63:107078.","journal-title":"Int J Antimicrob Agents"},{"key":"425_CR78","doi-asserted-by":"crossref","unstructured":"Destache CJ, Isern R, Kenny D, El-Herte R, Plambeck R, Palmer C et al. Impact of extracorporeal membrane oxygenation (ECMO) on serum concentrations of cefepime. Antibiot (Basel). 2024;13.","DOI":"10.20944\/preprints202410.1638.v1"},{"key":"425_CR79","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1186\/s13054-024-05101-z","volume":"28","author":"M Kim","year":"2024","unstructured":"Kim M, Mahmood M, Estes LL, Wilson JW, Martin NJ, Marcus JE, et al. A narrative review on antimicrobial dosing in adult critically ill patients on extracorporeal membrane oxygenation. Crit Care. 2024;28:326.","journal-title":"Crit Care"},{"key":"425_CR80","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","volume":"46","author":"MH Abdul-Aziz","year":"2020","unstructured":"Abdul-Aziz MH, Alffenaar JC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. Intensive Care Med. 2020;46:1127\u201353.","journal-title":"Intensive Care Med"},{"key":"425_CR81","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/FTD.0000000000000710","volume":"42","author":"GG Rao","year":"2020","unstructured":"Rao GG, Konicki R, Cattaneo D, Alffenaar JW, Marriott DJE, Neely M. Therapeutic drug monitoring can improve linezolid dosing regimens in current clinical practice: A review of linezolid pharmacokinetics and pharmacodynamics. Ther Drug Monit. 2020;42:83\u201392.","journal-title":"Ther Drug Monit"},{"key":"425_CR82","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/FTD.0000000000000941","volume":"44","author":"E Matusik","year":"2022","unstructured":"Matusik E, Boidin C, Friggeri A, Richard JC, Bitker L, Roberts JA, et al. Therapeutic drug monitoring of antibiotic drugs in patients receiving continuous renal replacement therapy or intermittent hemodialysis: A critical review. Ther Drug Monit. 2022;44:86\u2013102.","journal-title":"Ther Drug Monit"},{"key":"425_CR83","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.cmi.2017.01.005","volume":"23","author":"T Huwyler","year":"2017","unstructured":"Huwyler T, Lenggenhager L, Abbas M, Ing Lorenzini K, Hughes S, Huttner B, et al. Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study. Clin Microbiol Infect. 2017;23:454\u20139.","journal-title":"Clin Microbiol Infect"},{"key":"425_CR84","first-page":"497","volume":"81","author":"M Beumier","year":"2015","unstructured":"Beumier M, Casu GS, Hites M, Wolff F, Cotton F, Vincent JL, et al. Elevated \u03b2-lactam concentrations associated with neurological deterioration in ICU septic patients. Minerva Anestesiol. 2015;81:497\u2013506.","journal-title":"Minerva Anestesiol"},{"key":"425_CR85","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1093\/jac\/dkx209","volume":"72","author":"S Imani","year":"2017","unstructured":"Imani S, Buscher H, Marriott D, Gentili S, Sandaradura I. Too much of a good thing: a retrospective study of \u03b2-lactam concentration-toxicity relationships. J Antimicrob Chemother. 2017;72:2891\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"425_CR86","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1093\/cid\/ciac506","volume":"75","author":"R Pai Mangalore","year":"2022","unstructured":"Pai Mangalore R, Ashok A, Lee SJ, Romero L, Peel TN, Udy AA, et al. Beta-Lactam antibiotic therapeutic drug monitoring in critically ill patients: A systematic review and Meta-Analysis. Clin Infect Dis. 2022;75:1848\u201360.","journal-title":"Clin Infect Dis"},{"key":"425_CR87","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/cpt.2202","volume":"109","author":"SG Wicha","year":"2021","unstructured":"Wicha SG, M\u00e4rtson AG, Nielsen EI, Koch BCP, Friberg LE, Alffenaar JW, et al. From therapeutic drug monitoring to Model-Informed precision dosing for antibiotics. Clin Pharmacol Ther. 2021;109:928\u201341.","journal-title":"Clin Pharmacol Ther"},{"key":"425_CR88","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s40262-020-00937-4","volume":"60","author":"Y Cheng","year":"2021","unstructured":"Cheng Y, Wang CY, Li ZR, Pan Y, Liu MB, Jiao Z. Can population pharmacokinetics of antibiotics be extrapolated?? Implications of external evaluations. Clin Pharmacokinet. 2021;60:53\u201368.","journal-title":"Clin Pharmacokinet"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00425-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-025-00425-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00425-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T05:25:16Z","timestamp":1742189116000},"score":1,"resource":{"primary":{"URL":"https:\/\/jphcs.biomedcentral.com\/articles\/10.1186\/s40780-025-00425-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":88,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["425"],"URL":"https:\/\/doi.org\/10.1186\/s40780-025-00425-6","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"assertion":[{"value":"13 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}